Circassia Achieves Successful Phase II Clinical Results With Toleromune(R) Anti-Allergy Technology

Circassia Ltd, a specialty biopharmaceutical company focused on controlling immune system responses, announced positive results from a phase II clinical study of its anti-allergy technology, ToleroMune(R), in the field of cat allergy. The trial showed that ToleroMune treatment can substantially reduce allergic reactions to the allergen that causes most cat allergies, and importantly was well tolerated by all patients.

More: continued here

Filed under: Allergies on September 12th, 2008